VistaGen Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>VT</div>
VTGN -- USA Stock  

USD 2.12  0.28  11.67%

While some of us are excited about healthcare space, it makes sense to outline VistaGen Therapeutics in greater detail to make a better perception of its potential. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on the market and returns on VistaGen Therapeutics appear somewhat sensitive to each other for the last few months. Conflicting basic indicators of the company may also entail signs of long-standing losses for VistaGen institutional investors. The stock is still going through an active upward rally.
Published over two weeks ago
View all stories for VistaGen Therapeutics | View All Stories
Will VistaGen Therapeutics (NASDAQ:VTGN) price continue to rise in February?
This firm's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on VistaGen Therapeutics market sentiment investors' perception of the future value of VistaGen. Let us look at a few aspects of VistaGen technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of VistaGen Therapeutics. In general, we focus on analyzing VistaGen Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build VistaGen Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of VistaGen Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for VistaGen Therapeutics, we also check how macroeconomic factors affect VistaGen Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of VistaGen Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of VistaGen Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as VistaGen Therapeutics. Your research has to be compared to or analyzed against VistaGen Therapeutics' peers to derive any actionable benefits. When done correctly, VistaGen Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in VistaGen Therapeutics.

How does VistaGen Stands against Peers?

Analyzing VistaGen Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to VistaGen Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out VistaGen Therapeutics Competition Details

How VistaGen utilizes its cash?

To perform a cash flow analysis of VistaGen Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash VistaGen Therapeutics is receiving and how much cash it distributes out in a given period. The VistaGen Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

VistaGen Therapeutics exotic insider transaction detected

Legal trades by VistaGen Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
VistaGen insider trading alert for general transaction of common stock by Jon Saxe, the corporate stakeholder, on 24th of August 2020. This event was filed by Vistagen Therapeutics Inc with SEC on 2020-08-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at VistaGen Therapeutics Standard Deviation

VistaGen Therapeutics has current Standard Deviation of 7.7. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation 
=  
SQRT(V) 
 = 
7.7
SQRT = Square root notation
V =   Variance of VistaGen Therapeutics returns
Let's now compare VistaGen Therapeutics Standard Deviation to its closest peers:
VTGN
REGN
ALXN
WXXWY
IMMU
VTGN7.700683805803809
REGN2.0
ALXN4.07
WXXWY8.73
IMMU12.24

VistaGen Therapeutics implied volatility may change after the rise

The skewness is down to 3.83 as of today. VistaGen Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize VistaGen Therapeutics independently to ensure intended market timing strategies are aligned with expectations about VistaGen Therapeutics volatility.

Our Conclusion on VistaGen Therapeutics

Whereas few other entities under the biotechnology industry are still a bit expensive, VistaGen Therapeutics may offer a potential longer-term growth to institutional investors. On the whole, as of the 4th of January 2021, our analysis shows that VistaGen Therapeutics almost neglects market trends. The company is undervalued and projects low probability of distress for the next 2 years. However, our ongoing 30 days buy-hold-sell advice on the company is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of VistaGen Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com